
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is experiencing robust growth in its FSP, RWE, and CSMS segments, with notable year-over-year increases in Q3. The company is capitalizing on improved client decision timelines and a strong pipeline, bolstered by recent drug launches, which have contributed to a positive commercial momentum. Furthermore, IQVIA's improved pricing environment, alongside a significant enhancement in their win rate, positions the company well for sustained performance, with a projected growth rate of over 4% in its R&DServices segment on a constant currency, excluding COVID-related impacts.
Bears say
The financial analysis indicates a deteriorating outlook for IQVIA Holdings, driven primarily by a decline in year-over-year constant currency growth rates, which have dropped significantly from 6.8% in 2Q25 to 3.8% in the most recent quarter. Furthermore, the company's acknowledgment of potential challenges in maintaining 2026 revenue growth above 5% raises concerns about its ability to sustain momentum, particularly in the Real World Evidence (RWE) segment, which is expected to face tough comparisons. Additionally, rising interest rates pose a further risk to earnings, as the company navigates the impact of its floating versus fixed-rate debt obligations amidst a slowdown in hiring and operational productivity.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares